Atypical Stevens–Johnson syndrome caused by pembrolizumab in the treatment of metastatic melanoma – Are corticosteroids a safe treatment option?

Atypical Stevens–Johnson syndrome caused by pembrolizumab in the treatment of metastatic melanoma – Are corticosteroids a safe treatment option?

Pembrolizumab is a humanized monoclonal antibody that targets programmed cell death receptor-1. Stevens–Johnson syndrome (SJS) secondary to pembrolizumab has rarely been described in the treatment of malignant melanoma (MM). A 62-year-old woman developed a widespread bullous eruption following admin...

Full description

Bibliographic Details
Main Authors: Cathal O'Connor, Emmet Jordan, Michael O'Connell
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Journal of Dermatology and Dermatologic Surgery
Subjects:
corticosteroids
melanoma
pembrolizumab
stevens–johnson syndrome
Online Access:http://www.jddsjournal.org/article.asp?issn=2352-2410;year=2020;volume=24;issue=2;spage=137;epage=139;aulast=O'Connor

Internet

http://www.jddsjournal.org/article.asp?issn=2352-2410;year=2020;volume=24;issue=2;spage=137;epage=139;aulast=O'Connor

Similar Items